Neurelis’ mission is to build a leading neuroscience company that advances the care of patients suffering from neurological conditions. To do so, Neurelis is developing multiple wholly-owned product candidates utilizing Intravail®, for underserved acute neurological conditions. Product candidates include NRL-4 (acute agitation), NRL-2 (acute panic attacks), and NRL-3 (status epilepticus). In addition, Neurelis is developing NRL-1049, a new chemical entity for the treatment of cerebral cavernous malformations. If approved, NRL-1049 could be the first FDA-approved treatment for patients with this condition. Neurelis has also partnered with select program product candidates, including TOSYMRA® (acute migraine), NEFFY™ (anaphylaxis), OPNT003 (opioid overdose), and OPNT002 (alcohol use disorder).